Table 2.

Coagulation factors and inhibitors at baseline and after 24 weeks in men treated with placebo and testosterone replacement therapy.

	Placebo			Testosterone replacement therapy
Variable	Baseline	24 weeks	P	Baseline	24 weeks	P
N	20	20		17	17
Coagulation factor VII (%)	126 ± 23	120 ± 28	0.13	118 ± 21	101 ± 21	<0.001
Coagulation factor X (%)	119 ± 20	118 ± 19	0.87	119 ± 19	110 ± 13	<0.01
Prothrombin (%)	111 ± 14	109 ± 12	0.22	106 ± 12	97 ± 9	<0.01
Protein C (%)	128 ± 29	127 ± 31	0.70	120 ± 26	107 ± 20	<0.01
Free protein S (%)	111 ± 14	110 ± 16	0.53	107 ± 19	112 ± 16	<0.01
Tissue factor pathway inhibitor (ng/mL)a	31.1 ± 1.25	30.1 ± 1.27	0.33	30.1 ± 1.25	28.3 ± 1.26	<0.05
Antithrombin (%)	100 ± 10	100 ± 8	0.97	94 ± 12	91 ± 13	0.08
Coagulation factor XII (%)	134 ± 29	131 ± 29	0.47	136 ± 28	123 ± 27	<0.01
C1 esterase inhibitor (%)	88 ± 20	83 ± 21	0.10	91 ± 26	84 ± 25	<0.05

Data presented as mean ± s.d. were compared at baseline and 24 weeks with a paired t-test. Significant differences are highlighted in bold.^aTissue factor pathway inhibitors were logarithmically transformed before analysis (geometric mean ± s.d.).